Vara secures $8.9 million funding to advance AI-driven breast cancer detection

Berlin-based Vara, an AI-driven early breast cancer detection platform, has successfully raised $8.9 million in a fresh fundraising round. Founded in 2018 by Jonas Muff and Stefan Bunk, who serve as CEO and CTO respectively, Vara is enhancing the precision and efficiency of breast cancer detection through its advanced AI-powered software. With its headquarters in Berlin and a significant presence in India, the company is making substantial strides in the healthcare sector.

Vara’s AI software is a key component in Germany’s National Breast Cancer Screening Program, serving 40 per cent of the country’s screening centres. This integration represents the first large-scale deployment of an AI system within the national program, assisting over 80,000 women each month. Achievements under this initiative include the evaluation of over 100,000 images monthly, a noticeable increase in cancer detection rates—particularly identifying 50 per cent of the cancers that might have been overlooked by radiologists—and a reduction in the incidence of false positives. Additionally, the software has enhanced workflow efficiency for medical professionals involved in the screening process.

Aims of further global expansion have led Vara to enter emerging healthcare markets such as India. In 2023, the platform entered into a partnership with NM Medical, a prominent provider of imaging services with operations in Mumbai, Bangalore, and Pune. The collaboration focuses on enhancing the standard of preventive care and early breast cancer detection in India, placing particular emphasis on mammography as a pivotal element of women’s health programs.

Jonas Muff expressed the importance of the new funding amidst challenging economic conditions, underscoring that it not only acknowledges the credibility of their technology but also propels Vara’s international expansion. He expressed satisfaction with the positive outcomes being observed through partnerships in the healthcare industry and alluded to future advancements that the company aims to achieve.

This financial boost was co-led by impact-focused funds, with notable contributions from IBB Ventures and European family offices such as Smart Family Office (Austria) and FJH (Germany). Ute Mercker, Investment Director at IBB Ventures, remarked on Vara’s alignment with their impact fund’s objectives through the integration of an AI-driven screening strategy and its proven efficacy in medical settings, along with commercial expansion in emerging markets.

In addition to securing fresh funds, Vara has disseminated a significant study in collaboration with The Lancet Digital Health. The research, titled “Strategies for integrating artificial intelligence into mammography screening programmes: a retrospective simulation analysis,” utilised nearly two million datasets from the UK, Sweden, and Germany. The study revealed notable advancements in essential screening parameters, including heightened cancer detection rates, reduced recall rates, and decreased workload for radiologists.

Vara continues to position itself as a pioneering force in AI-enabled healthcare solutions, with its recent achievements underscoring its commitment to improving breast cancer detection on a global scale.

Source: Noah Wire Services